Fig. 7: The SIRT6 inhibitor OSS_128167 (OSS) preventes airway remodeling in asthmatic mice.

a Chemical Structure of OSS_128167 (OSS) is shown. b Schematic overview of experimental design for (b–j) in an ASA model. c Representative photomicrographs of lung inflammation expression are shown (Control n = 4; HDM + LPS n = 5, HDM + LPS + OSS n = 6). Scale bars, 100 μm. d, e The expression of RORγt, SIRT6, and IL-17A in the lung homogenate from mice treated with HDM/LPS or mice treated with HDM/LPS and SIRT6 inhibitor OSS_128167 (OSS) was analyzed by using Western blot. Quantification was analyzed by Image J software. f, g ELISA and qRT-PCR analysis of IL-17A in lung homogenate of mice. h–j The expression of inflammatory cytokines in the lung homogenate of mice was analyzed by using qRT-PCR or ELISA analysis. k Schematic overview of experimental design for (L-O) in a chronic severe asthma (CSA) model. (Control n = 4; HDM + LPS n = 5, HDM + LPS + OSS n = 5). l The expression of N-ca, Muc5ac, Collagen I, α-Sma, and Mmp9 expression in the lung homogenate of mice was analyzed by using qRT-PCR. m Representative periodic acid-Schiff (PAS) staining, Masson, and α-SMA of lung sections from WT mice treated with HDM/LPS or HDM/LPS plus SIRT6 inhibitor OSS. Scale bars, 100 μm. n, o The expression of N-Ca, Collagen I, and α-SMA in the lung homogenate of mice were analyzed by using Western blot. Quantification was analyzed by Image J software. Data are shown as means ± SEM and three or more independent experiments were performed. Significance was calculated by one-way ANOVA followed by Tukey’s post-hoc test for (e–j–l–o).